首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1917746

大腸直腸癌篩檢市場－2026-2031年預測

Colorectal Cancer Screening Market - Forecast from 2026 to 2031

出版日期: 2026年01月05日 | 出版商:

Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

大腸直腸癌篩檢市場正以 4.3% 的複合年成長率擴張，預計將從 2025 年的 157.94 億美元成長到 2031 年的 203.29 億美元。

大腸直腸癌 (CRC) 篩檢市場是全球體外診斷和預防醫學領域的重要組成部分，專注於檢測結腸和直腸的癌前息肉和早期惡性腫瘤。由於 CRC 通常由腺瘤性息肉緩慢發展而來，因此篩檢至關重要，為早期發現和預防提供了重要機會。該市場涵蓋多種檢測方式，包括糞便檢驗（糞便免疫化學檢查、多靶點糞便 DNA 檢測）、直接可視化技術（大腸鏡檢查、乙狀結腸鏡檢查、膠囊內視鏡檢查）以及新興的血液檢測。市場成長的驅動力主要來自疾病負擔的加重、人口結構的變化以及為提高篩檢的可及性和依從性而不斷加大的力度。

主要市場成長要素

市場擴張與全球大腸直腸癌發生率和疾病負擔的不斷加重密切相關。大腸直腸癌仍然是世界上最常見的癌症之一。其發病率的上升，尤其是在年輕人群和生活方式改變的地區，凸顯了大規模篩檢計畫的緊迫性。這種流行病學趨勢正在形成一個持續成長的篩檢和治療目標族群。

一些已確立且普遍存在的可改變風險因素進一步加劇了這一負擔。主要的生活方式因素包括缺乏運動、低纖維高加工食品飲食、肥胖和吸煙。隨著都市化和經濟狀況的變化，這些風險因素在全球範圍內不斷增加，導致人群整體風險水平升高，這進一步凸顯了廣泛篩檢措施的必要性和合理性。

最重要的人口因素是世界人口老化。雖然大腸直腸癌 (CRC) 的發生率在年輕人中呈上升趨勢，但50歲以後風險顯著增加。 50歲及以上人口的持續成長，尤其是在已開發經濟體，是篩檢計畫的重要目標族群。這種人口結構變化直接導致檢測量增加，因為臨床建議接受篩檢的人數龐大且持續成長。

此外，公眾意識的提高和系統性的公共衛生措施是關鍵的推動因素。政府主導的宣傳活動、專業學會的指南以及教育工作提高了公眾和醫療衛生人員對大腸直腸癌可預防性的認知。美國預防服務工作小組（USPSTF）等主要指引已將建議篩檢年齡降低至45歲，擴大了目標人口。這些努力旨在消除公眾意識障礙和社會偏見，從而直接提高篩檢參與率。

市場區隔和不斷發展的測試方法

市場特徵是多種檢測方式並存，每種方式各有優勢，並根據患者偏好和醫療系統資源進行選擇。糞便檢驗，特別是大便潛血試驗（FIT），因其非侵入性、低成本和易用性而被廣泛用於大規模篩檢。多標靶糞便DNA檢測（例如Cologuard）在檢測晚期病變方面表現出高靈敏度，使其成為高階非侵入性檢測選擇。大腸鏡檢查仍然是診斷和治療的黃金標準，能夠發現病變並即時切除息肉。創新的重點在於提高非侵入性偵測的準確性和易用性，以及改善內視鏡檢查的體驗和效率。

區域展望：北美市場表現強勁

預計北美將繼續在全球大腸癌篩檢市場佔據重要佔有率。這一地位得益於其成熟的篩檢基礎設施、醫護人員和公眾的高度認知、多種篩檢方式完善的報銷機制以及較高的風險因素盛行率。主要企業的存在以及對新型檢測方法的積極法規環境，進一步鞏固了該地區作為創新和應用關鍵市場的地位。

競爭格局與策略重點

競爭格局包括大規模診斷公司、專業分子診斷公司和醫療設備製造商。競爭重點在於檢測性能特徵（靈敏度、特異性）、易用性、成本效益以及與臨床工作流程的整合。策略創新主要集中在以下幾個關鍵領域：

基於血液的液態生物檢體：開發微創血液檢測方法來檢測循環腫瘤 DNA (ctDNA) 和其他與大腸直腸癌相關的生物標記物，由於血液採集方便，這可能會促進檢測的普及。
推進糞便檢驗：提高早期癌症和進行性腺瘤的非侵入性檢測的敏感度，同時保持特異性並減少假陽性。
內視鏡技術的演進：高清成像和虛擬染色內視鏡等影像技術的進步，以及人工智慧工具的進步，將提高大腸鏡檢查期間腺瘤的檢出率。
數位化參與：利用數位平台和病患導航服務來提高篩檢的啟動率和完成率，尤其是在服務不足的人群中。

未來展望與戰略考量

受人口結構變化和臨床界對早期檢測價值的廣泛認可的推動，結直腸癌篩檢市場預計將持續成長。未來，市場發展將受到以下因素的影響：透過更易於接受和使用的檢測方法提高篩檢參與率；以及轉向基於風險分層的篩檢方法，從而根據遺傳、家族史和生活方式等因素提供個人化建議。

對於產業相關人員，策略成功取決於能否獲得可靠的臨床證據以支持新技術納入指南，向支付方證明其成本效益，以及與醫療系統和公共衛生組織建立夥伴關係，從而實施綜合篩檢路徑。此外，如何因應國際上不同的報銷環境，以及如何解決篩檢取得的健康差異，也將是關鍵挑戰。作為癌症預防的基礎，大腸直腸癌篩檢市場的成長與全球公共衛生使命密不可分，即透過積極主動、實證的干涉措施來降低癌症死亡率。

本報告的主要優勢：

深入分析：獲得主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
競爭格局：了解全球主要企業的策略舉措，並了解透過正確的策略進入市場的可能性。
市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
可操作的建議：利用這些見解，在動態環境中做出策略決策，並開拓新的商機和收入來源。
受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

以下是一些公司如何使用這份報告的範例

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

2021年至2025年的實際數據和2026年至2031年的預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區（包括國家）分類的收入和預測評估
公司概況（策略、產品、財務資訊、關鍵發展等）

The colorectal cancer (CRC) screening market is a critical segment within the global in-vitro diagnostics and preventive healthcare landscape, focused on the detection of precancerous polyps and early-stage malignancies in the colon and rectum. Screening is paramount, as CRC typically develops slowly from adenomatous polyps, providing a significant window for interception and prevention. The market encompasses a range of modalities, including stool-based tests (fecal immunochemical tests, multitarget stool DNA tests), direct visualization techniques (colonoscopy, sigmoidoscopy, capsule endoscopy), and emerging blood-based assays. Market growth is driven by a powerful combination of rising disease burden, demographic shifts, and increasing efforts to improve screening accessibility and adherence.

Primary Market Growth Drivers

The expansion of the market is fundamentally linked to the rising global prevalence and burden of colorectal cancer. CRC remains one of the most commonly diagnosed cancers worldwide. The increasing incidence, particularly notable in younger age cohorts and in regions undergoing lifestyle transitions, underscores the urgent need for scalable screening programs. This epidemiological trend creates a sustained and growing addressable population for screening tests and procedures.

This burden is exacerbated by well-established and pervasive modifiable risk factors. Key lifestyle drivers include sedentary behavior, dietary patterns low in fiber and high in processed foods, obesity, and tobacco use. The global increase in these risk factors, linked to urbanization and changing socio-economic conditions, contributes to a higher population-wide risk profile, further justifying and necessitating broad screening initiatives.

A paramount demographic driver is the global aging of the population. While CRC incidence is rising in younger adults, the risk escalates significantly after age 50. The expanding demographic of adults over 50, particularly in developed economies, represents the core target population for organized screening programs. This demographic shift ensures a large and growing pool of individuals for whom screening is clinically recommended, directly driving test volumes.

Furthermore, increasing awareness and structured public health initiatives are critical catalysts. Government-led campaigns, professional society guidelines, and advocacy work have elevated public and clinical understanding of CRC as a preventable disease. The lowering of recommended screening initiation age to 45 in key guidelines, such as those from the U.S. Preventive Services Task Force, has expanded the eligible population. These efforts aim to overcome barriers of awareness and stigma, directly translating into higher screening participation rates.

Market Segmentation and Evolving Modalities

The market is characterized by a multi-modal approach, each with distinct advantages catering to different preferences and healthcare system resources. Stool-based tests, particularly fecal immunochemical tests (FIT), are widely used for population-based screening due to their non-invasiveness, low cost, and ease of use. Multitarget stool DNA tests (e.g., Cologuard) offer higher sensitivity for detecting advanced lesions, representing a premium non-invasive option. Colonoscopy remains the gold standard diagnostic and therapeutic procedure, allowing for both detection and immediate polyp removal. Innovation is focused on improving the accuracy and user-friendliness of non-invasive tests and enhancing the experience and efficiency of endoscopic procedures.

Geographical Outlook: North American Market Strength

North America is expected to maintain a significant share of the global colorectal cancer screening market. This position is supported by a mature screening infrastructure, high awareness levels among both providers and the public, well-established reimbursement pathways for multiple screening modalities, and a high prevalence of risk factors. The presence of leading diagnostic companies and a proactive regulatory environment for novel tests further consolidates the region's role as a primary market for innovation and adoption.

Competitive Landscape and Strategic Focus

The competitive landscape includes large, diversified diagnostic corporations, specialized molecular diagnostics companies, and medical device firms. Competition centers on test performance characteristics (sensitivity, specificity), ease of use, cost-effectiveness, and integration into clinical workflows. Strategic innovation is directed toward several key areas:

Blood-Based Liquid Biopsies: Developing minimally invasive blood tests that detect circulating tumor DNA (ctDNA) or other biomarkers associated with CRC, potentially improving compliance by offering a simple blood draw.
Enhanced Stool Tests: Improving the sensitivity of non-invasive tests for early-stage cancer and advanced adenomas while maintaining specificity to reduce false positives.
Endoscopic Technology: Advancing imaging capabilities (e.g., high-definition, virtual chromoendoscopy) and artificial intelligence tools to improve adenoma detection rates during colonoscopy.
Digital Engagement: Utilizing digital platforms and patient navigation services to increase screening initiation and completion rates, particularly in underserved populations.

Future Trajectory and Strategic Considerations

The colorectal cancer screening market is poised for continued growth, propelled by demographic inevitability and the strong clinical consensus on the value of early detection. Future evolution will be shaped by the pursuit of higher screening participation rates through more acceptable and accessible tests, and the move towards risk-stratified screening approaches that personalize recommendations based on genetic, familial, and lifestyle factors.

For industry participants, strategic success will depend on generating robust clinical evidence to support new technologies in guidelines, demonstrating cost-effectiveness to payers, and forming partnerships with health systems and public health organizations to implement integrated screening pathways. Navigating diverse international reimbursement landscapes and addressing health equity in screening access will also be critical challenges. As a cornerstone of cancer prevention, the CRC screening market's growth is inextricably linked to the global public health mission of reducing cancer mortality through proactive, evidence-based intervention.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Colorectal Cancer Screening Market Segmentation

By Screening Test
Flexible Sigmoidoscopy
Stool-based Tests
CT Colonography
Colonoscopy
Others
By End-User
Independent Diagnostic Labs
Hospitals
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. COLORECTAL CANCER SCREENING MARKET BY SCREENING TEST

5.1. Introduction
5.2. Flexible Sigmoidoscopy
5.3. Stool-based Tests
5.4. CT Colonography
5.5. Colonoscopy
5.6. Others

6. COLORECTAL CANCER SCREENING MARKET BY END-USER

6.1. Introduction
6.2. Independent Diagnostic Labs
6.3. Hospitals
6.4. Others

7. COLORECTAL CANCER SCREENING MARKET BY GEOGRAPHY

7.1. Introduction
7.2. North America
- 7.2.1. USA
- 7.2.2. Canada
- 7.2.3. Mexico
7.3. South America
- 7.3.1. Brazil
- 7.3.2. Argentina
- 7.3.3. Others
7.4. Europe
- 7.4.1. Germany
- 7.4.2. France
- 7.4.3. United Kingdom
- 7.4.4. Spain
- 7.4.5. Others
7.5. Middle East and Africa
- 7.5.1. Saudi Arabia
- 7.5.2. UAE
- 7.5.3. Others
7.6. Asia Pacific
- 7.6.1. China
- 7.6.2. India
- 7.6.3. Japan
- 7.6.4. South Korea
- 7.6.5. Indonesia
- 7.6.6. Thailand
- 7.6.7. Others